210 related articles for article (PubMed ID: 16343176)
1. Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
Lorusso D; Ferrandina G; Fruscella E; Marini L; Adamo V; Scambia G
Int J Gynecol Cancer; 2005; 15(6):1002-13. PubMed ID: 16343176
[TBL] [Abstract][Full Text] [Related]
2. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
3. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine in ovarian cancer.
Orlando M; Mandachain M
Semin Oncol; 2001 Jun; 28(3 Suppl 10):62-9. PubMed ID: 11510036
[TBL] [Abstract][Full Text] [Related]
5. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Matsumoto K; Onda T; Yaegashi N
Jpn J Clin Oncol; 2015 May; 45(5):408-10. PubMed ID: 25765457
[TBL] [Abstract][Full Text] [Related]
7. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF; Meydanli MM; Tulunay G
Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
[TBL] [Abstract][Full Text] [Related]
9. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
11. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Chanpanitkitchot S; Tangjitgamol S; Khunnarong J; Thavaramara T; Pataradool K; Srijaipracharoen S
Asian Pac J Cancer Prev; 2014; 15(13):5215-21. PubMed ID: 25040977
[TBL] [Abstract][Full Text] [Related]
14. Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Pectasides D; Psyrri A; Pectasides M; Economopoulos T
Expert Opin Pharmacother; 2006 Jun; 7(8):975-87. PubMed ID: 16722809
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
16. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
Watanabe Y; Koike E; Nakai H; Etoh T; Hoshiai H
Int J Clin Oncol; 2008 Aug; 13(4):345-8. PubMed ID: 18704636
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
19. Optimizing gemcitabine regimens in ovarian cancer.
Pecorelli S; Pasinetti B; Tisi G; Odicino F
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
[TBL] [Abstract][Full Text] [Related]
20. Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Dohrmann T; Kutup A; Mahner S; Müller V; Jaenicke F; Izbicki JR; Vashist YK
J Clin Oncol; 2013 Apr; 31(12):e208-10. PubMed ID: 23509305
[No Abstract] [Full Text] [Related]
[Next] [New Search]